What this means
This is a multi-cohort, open-label, adaptive trial designed to evaluate the safety, tolerability, and biological effects of dietary supplements and other aging-targeted therapies. Cohort 1 is a single-arm, open-label, intrapatient dose-escalation study evaluating the effects of escalating doses of spermidine in 10 participants.
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Active not recruiting
- Who can join
- Ages 18–75
- Where
- 1 site, including New York
The science
- Registered title
- Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies
- Trial ID
- NCT07202403 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Aging, Longevity
- What is tested
- Spermidine
- Sponsor
- Atria Research and Global Health Institute (ARGHI)
- Ages
- 18 Years to 75 Years
- Dates
- First posted Oct 1, 2025 · updated Oct 27, 2026
Registry summary
This is a multi-cohort, open-label, adaptive trial designed to evaluate the safety, tolerability, and biological effects of dietary supplements and other aging-targeted therapies.
Cohort 1 is a single-arm, open-label, intrapatient dose-escalation study evaluating the effects of escalating doses of spermidine in 10 participants. Patients will have baseline blood drawn and subsequently start daily administration of spermidine. They will receive capsules for three consecutive 28-day courses with escalating doses of 40mg, 120mg, and 400mg.
Subsequent cohorts will evaluate additional agents.
Sites (1)
- Atria Research and Global Health Institute, New York, New York, United States